PT  - JOURNAL ARTICLE
AU  - Amir Babiker
AU  - Vipan Datta
TI  - Lipoatrophy with insulin analogues in type I diabetes
AID  - 10.1136/adc.2010.183731
DP  - 2011 Jan 01
TA  - Archives of Disease in Childhood
PG  - 101--102
VI  - 96
IP  - 1
4099  - http://adc.bmj.com/content/96/1/101.short
4100  - http://adc.bmj.com/content/96/1/101.full
SO  - Arch Dis Child2011 Jan 01; 96
AB  - Lipoatrophy is a rare complication of treatment with insulin analogues. It has been reported with insulin Lispro (Eli Lilly, Indianapolis, Indiana, USA) and insulin Glargine (Sanofi-Aventis, Paris, France). To our knowledge, this is one of the first reports of lipoatrophy with Aspart, biphasic Aspart and Detemir insulin analogues (Novo Nordisk, Bagsvaerd, Denmark). We report the cases of four children with type I diabetes who were commenced on NovoMix 30 or NovoRapid/Levemir insulin injections. They developed lipoatrophy at the injection sites after 2–3 years of treatment. In two of our patients, lipoatrophy resolved when the injection sites were changed, suggesting that local factors could be the cause of lipoatrophy. However, lipoatrophy developed at the new sites in the other two patients, requiring a change of insulin preparation. Regular examination of the injection sites facilitated early detection of lipoatrophy in our patients. Lipoatrophy completely resolved over 1–2 years in all patients with no recurrence after 3–4 years of follow-up.